A Domestic Outbreak of Bacterial Dysentery Caused by Extended-Spectrum beta-Lactamase (ESBL) -producing Shigella sonnei / 소아과

PURPOSE: An outbreak of ESBL-producing Shigella sonnei enteritis was unprecedented not only in Korea but throughout the world in the past. We intended to devise a management guideline for ESBL-producing shigellosis based on analysis of clinical manifestations and response to therapy. METHODS: We analyzed 103 patients who were admitted to the hospital with acute GI symptoms and were shown positive result for S. sonnei on stool culture. We performed sensitivity test to the antibiotics and DNA sequencing of ESBL gene in the isolated S. sonnei colonies. In addition, we retrospectively analyzed their clinical characteristics, laboratory results, and clinical and microbiological responses to the antibiotics. RESULTS: Among the clinical manifestations, fever was the most frequent (96.1%), followed by diarrhea (93.2%), abdominal pain (76.7%), headache (71.8%), vomiting (65.0%), and nausea (41.7%). The fever was sustained for average of 2.0 days and diarrhea for 3.9 days. Watery diarrhea was the most common (69%) followed by mucoid (26%), and bloody stool (5%). On peripheral blood smear, leukocytosis was noted in 53.4% of patients, and 78.6% of patients tested positive for serum CRP response. On stool direct smear, 11.7% of patients showed more than 50 WBCs/HPF, and 9.7% of patients between 5 to 20 WBCs/HPF. Stool occult blood was positive in 71% of patients. Production of CTX-M-14 type ESBL was reported for all S. sonnei strains isolated from this outbreak. Microbiological eradication rates to various antibiotics were as follows: 100% (9/9) to ciprofloxacin, 100% 5/5) to azithromycin, 6.9% (5/72) to cefdinir, 0% (0/8) to ceftriaxone, 12.5% (1/8) to ceftizoxime, 0% (0/ 8) to TMP/SMX, 42.9% (3/7) to ampicillin/sulbactam, 20% (1/5) to amoxicillin/clavulanic acid, and 68.8 % (11/16) to imipenem/cilastatin. CONCLUSION: It is presumed that azithromycin can be an attractive option for the treatment of ESBL-producing S. sonnei enteritis in pediatric population, given its cost-effectiveness and safety. Although ciprofloxacin is another cost-effective agent, its use in pediatric population may be a bit too premature.

Treatment of Childhood Idiopathic Thrombocytopenic Purpura with Anti-D (WinRho(R)) / 대한소아혈액종양학회지

PURPOSE: Anti-D immunoglobulin has recently emerged as a theraputic option for the treatment of patients with idiopathic thrombocytopenic purpura (ITP). There is no report about anti-D treatment in our country. In this report, the efficacy and adverse reactions of anti-D immunoglobulin in children with ITP were evaluated. METHPDS: From August, 1997 to September, 1998, 7 courses of anti-D treatment were applied in 4 children who had persisting thrombocytopenia and frequent bleeding episodes despite use of intravenous immunoglobulin and corticosteroid. They were Rh-positive and non-splenectomized patients. They received 43~60 mug/kg/dose of anti-D (WinRho ) twice with 7 days interval at out patient department. To evaluate the efficacy and adverse reactions of anti-D, platelet, reticulocyte, hemoglobin, bilirubin and haptoglobin counts were observed weekly. RESULTS: Median age and pretreatment duration after diagnosis were 22 months (15~77 months) and 7 months (2~46 months), respectively. Bleeding decreased significantly after anti-D treatment. Platelet count increased median 4.11 folds (1.85~13.67 folds) and response was maximal at day 7. Duration of platelet increase more than 2 folds was 5 weeks (0~10 weeks). No significant adverse reactions other than mild hemolytic anemia was present. Hemoglobin decreased to minimal 88% (79.5~95.9%) of pretreatment value. Duration of hemoglobin lower than 90% of pretreatment value was 1 week (0~4 weeks). After 10 weeks, platelet and hemoglobin returned to pretreatment value. CONCLUSION: Although anti-D is not a curative treatment for ITP, it is safe and repeated infusions of anti-D can be used to maintain the platelet count at a level of sufficient to provide adequate hemostasis and may enable children to postpone or even avoid splenectomy.